Litcius/Paper detail

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Julie N. Graff, Christopher Hoimes, Winald R. Gerritsen, Ulka N. Vaishampayan, Tony Elliott, Clara Hwang, Albert J. ten Tije, Aurelius Omlin, Raymond S. McDermott, Yves Fradet, Scott T. Tagawa, Deepak Kilari, Cristiano Ferrario, Hiroji Uemura, Robert J. Jones, Satoshi Fukasawa, Avivit Peer, Cuizhen Niu, Christian Poehlein, Ping Qiu, Leah Suttner, Ronald de Wit, Charles Schloss, Johann S. de Bono, Emmanuel S. Antonarakis

2024Prostate Cancer and Prostatic Diseases13 citationsDOI

Topics & Concepts

EnzalutamideMedicineProstate cancerPembrolizumabClinical endpointInternal medicineCohortOncologyResponse Evaluation Criteria in Solid TumorsCancerPhases of clinical researchUrologySurgeryClinical trialImmunotherapyAndrogen receptorProstate Cancer Treatment and ResearchCancer Immunotherapy and BiomarkersProstate Cancer Diagnosis and Treatment
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study | Litcius